NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 21:36இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Indegene Posts Q2 Revenue of ₹1,122.3 Cr, Up 39.5% YoY; Releases Earnings Call Transcript
Indegene Limited released the transcript of its Q2 FY27 earnings conference call held on October 30, 2026. The company reported quarterly revenues of ₹1,122.3 Cr (₹11,223 million), marking a 39.5% YoY growth and 5.6% sequential increase. Management highlighted 9 deal wins with annual contract value (ACV) above $1 million, including 3 large deals. Growth was supported by an expansion in active clients to 107 and a rise in TTM revenue per employee to $79,600 from $69,000 a year ago, driven by GenAI platform integration and outcome-based pricing models.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 FY27 earnings conference call conducted on October 30, 2026.
ஏன் இது முக்கியம்Provides granular operational color on deal pipeline conversion, pricing shifts toward outcome-based GenAI models, and management's outlook for H2 performance.
📅 குறுகிய காலம்Neutral to mildly positive as the transcript confirms strong operational commentary already disclosed during results, detailing healthy deal momentum into H2.
📈 நீண்ட காலம்Positive structural tailwinds as GenAI platform delivery and outcome-based pricing help expand revenue per employee and support operating leverage across global biopharma clients.
⚠ அபாய எச்சரிக்கைகள்
Client concentration with top 20 accounts remaining a significant growth driver
Execution and revenue recognition timing risks on large outcome-based contracts
👀 கவனிக்க வேண்டியவை
Track the ramp-up of large contract wins and margin expansion in Q3 and Q4, particularly the execution and revenue recognition curve of the $10 million outcome-based contract.
Indegene Q2 FY27: Revenue up 39.5% YoY to ₹1,122.3 Cr, EBITDA margin at 16.7%
Indegene reported strong Q2 FY27 operational results, with revenue from operations growing 39.5% YoY to ₹11,223 million ($117.5M), marking its fifth consecutive quarter of over 5% sequential growth. Operating EBITDA came in at ₹1,873 million (up 32.0% YoY) with an EBITDA margin of 16.7%, remaining stable despite absorption of annual wage hikes. Net profit (PAT) increased 10.0% YoY to ₹1,123 million, though it dipped 3.4% sequentially due to yield impacts on investments. The client base expanded meaningfully, with $1M+ clients rising to 59 compared to 40 in the prior-year period.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndegene published its Q2 FY27 investor presentation and fact sheet, showing continued top-line acceleration driven by Enterprise Commercial Solutions and large client expansion.
ஏன் இது முக்கியம்Demonstrates strong demand in life sciences commercialization, resilience against tech-spending cuts, and steady execution in monetizing GenAI capabilities across top biopharma accounts.
📅 குறுகிய காலம்Solid operational performance and guidance of margin improvements in H2 FY27 are likely to be viewed favourably by the market in upcoming sessions.
📈 நீண்ட காலம்Expansion in large-tier customer accounts ($1M+) and 60%+ outcome-aligned pricing models position the company structurally to capture GenAI-driven workflow transformations in life sciences.
⚠ அபாய எச்சரிக்கைகள்
Top-20 biopharma customer concentration remains elevated at 67.3% of total revenues.
North America represents 74.5% of sales, making performance sensitive to US healthcare regulatory policy shifts.
👀 கவனிக்க வேண்டியவை
Track margin expansion in H2 FY27 as management guided lower amortization (reduction of ₹56M per quarter) and full absorption of wage increases to improve operating leverage.
US Court grants preliminary approval for Indegene's max $4.72M class action lawsuit settlement
Indegene's US subsidiary, Indegene, Inc., has received preliminary approval from the US District Court, District of New Jersey, for a class action settlement under the Telephone Consumer Protection Act. The settlement framework caps the maximum settlement fund at approximately USD 4.72 million (~₹39.5 crore), structured on a claims-made basis with USD 250 payable per approved claim. Final approval hearing is scheduled for 12 January 2027 following the claims submission deadline on 9 December 2026. Given Indegene's TTM net profit of ₹401 crore, the capped liability represents less than 10% of annual profits and removes legal uncertainty.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe US District Court granted preliminary approval to the settlement agreement, setting formal timelines for class notices, claims submission, and final approval.
ஏன் இது முக்கியம்Caps the legal liability of Indegene's US subsidiary at a maximum of USD 4.72 million, minimizing financial uncertainty relative to its ₹401 crore TTM net profit.
Maximum Settlement Fund: USD 4.72 millionPayment per eligible claim: USD 250Claims deadline: 9 டிசம்பர் 2026Final approval hearing date: 12 ஜனவரி 2027
📅 குறுகிய காலம்Provides clarity and sets a clear legal timeline without immediate cash outflow, as no pre-funding or escrow is required.
📈 நீண்ட காலம்Clears an overhang from legacy class action litigation in the core US geography.
⚠ அபாய எச்சரிக்கைகள்
Settlement remains subject to final court approval following notice and objection periods.
👀 கவனிக்க வேண்டியவை
Track the claims submission deadline on 9 December 2026 and the final court approval hearing on 12 January 2027 to assess actual cash outflow.
Indegene Agrees to Settle US Class Action Fax Lawsuit with Max Fund Capped at $4.72M
Indegene Limited's US subsidiary, Indegene, Inc., has finalized terms for a definitive settlement agreement regarding a class-action lawsuit under the US TCPA concerning February 2020 fax communications. The agreement establishes a contractual maximum settlement fund of approximately USD 4.72 million (calculated at USD 250 per eligible claim across 18,851 unique fax numbers). The settlement operates on a claims-made and reversionary basis, meaning actual cash outflow will depend on verified claims and unspent funds will revert to the company without requiring upfront escrow. Against Indegene's TTM PAT of ₹401 Cr, the maximum exposure represents around 10%, effectively capping a long-standing legal overhang.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndegene has moved from mediation to authorizing execution of a definitive settlement agreement, capping its TCPA class action exposure at a maximum of USD 4.72M.
ஏன் இது முக்கியம்Resolves legal uncertainty dating back to 2020 at a manageable maximum financial impact (approx. ₹39-40 Cr max vs ₹401 Cr TTM PAT), with actual cash outflow likely lower due to the reversionary structure.
Maximum Settlement Fund: USD 4.72 millionPer-claim compensation: USD 250Certified Class Size: 18,851 unique fax numbersSettlement Admin Cost: USD 42,559Max Exposure vs TTM PAT: ~10%
📅 குறுகிய காலம்Removes legal uncertainty; market reaction should be neutral-to-mildly positive as the liability is now strictly defined and claims-dependent.
📈 நீண்ட காலம்Eliminates a historical pre-IPO litigation overhang from 2020 without material disruption to balance sheet or growth strategy.
⚠ அபாய எச்சரிக்கைகள்
Subject to formal execution and final approval by the U.S. District Court, District of New Jersey
👀 கவனிக்க வேண்டியவை
Track subsequent filings for US District Court preliminary and final approval milestones, as well as the final quantified claims impact reported in future quarterly financials.
39.7% YoY Revenue Growth in Q1 FY27; Active Clients Cross 100 Milestone
Indegene reported a strong start to FY27 with Q1 revenue reaching ₹1,063.1 cr, a 39.7% increase year-on-year and 6% quarter-on-quarter. The company successfully diversified its client base, with accounts outside the top 20 global pharma firms now contributing over 33% of total revenue. Key deal wins include one $3M-$5M contract and four $1M-$3M contracts, alongside a milestone of reaching 105 active clients. Management remains confident in FY27 being stronger than FY26, driven by AI-integrated commercialization services and expansion into new therapeutic areas.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndegene has delivered its strongest Q1 sequential growth in four years and successfully crossed the 100-active-client milestone while diversifying revenue away from its top 20 clients.
ஏன் இது முக்கியம்The results validate Indegene's specialized life-sciences model, showing that it can grow significantly faster than traditional IT services by embedding itself in the commercial 'revenue engine' of pharma companies rather than just the 'cost side'.
Q1 FY27 Revenue: ₹1,063.1 கோடிYoY Revenue Growth: 39.7%Q1 வருவாய் vs TTM வருவாய்: 30.3%Active Clients: 105Revenue per Employee (TTM): $77,000Top 20 Client Concentration: 65.5%
📅 குறுகிய காலம்The stock may see positive sentiment following the robust 39.7% YoY growth and management's optimistic outlook for FY27 being stronger than FY26.
📈 நீண்ட காலம்Indegene is structurally positioning itself to benefit from the 'patent cliff' facing big pharma, as companies require more efficient, AI-driven commercialization for wider drug portfolios.
⚠ அபாய எச்சரிக்கைகள்
High client concentration with top 20 pharma still contributing 65.5% of revenue
Potential pricing pressures from the US Inflation Reduction Act (IRA) impacting client spend
Talent attrition and wage inflation in specialized life-sciences roles
👀 கவனிக்க வேண்டியவை
Watch for the execution of the 'Agentic AOR' and 'Tectonic' engagements as they move from proof-of-concept to larger scale. Monitor if the company can maintain its 17-18% operating margins while investing in AI talent and integrating recent UK and US acquisitions.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
39.7% YoY Revenue Growth in Q1 FY27; Active Clients Reach 105
Indegene reported a strong start to FY27 with Q1 revenue growing 39.7% YoY to ‑1,063.1 Cr, driven by robust demand in Enterprise Commercial Solutions. While EBITDA margins contracted to 16.9% from 20.2% a year ago, PAT saw a sharp sequential recovery of 45.9% to ‑116.2 Cr. The company successfully diversified its client base, adding 35 active clients YoY to reach 105, and improved its Revenue per Employee to a record $77.1K. Cash reserves remain healthy at ‑1,460.2 Cr, representing approximately 11.6% of the current market capitalization.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndegene has significantly broadened its client base beyond the top 20 global biopharma firms while achieving its highest-ever revenue per employee.
ஏன் இது முக்கியம்The shift toward a more diversified client base reduces concentration risk, while the growth in outcome-aligned revenue (now ~60%) suggests a transition toward higher-value, technology-led delivery.
Q1 வருவாய்: ‑1,063.1 CrYoY Revenue Growth: 39.7%EBITDA லாப வரம்பு: 16.9%Revenue per Employee: $77.1KCash vs Market Cap: ~11.6%Active Clients: 105
📅 குறுகிய காலம்The strong top-line growth and sequential PAT recovery are likely to be viewed positively by the market in the coming weeks.
📈 நீண்ட காலம்The structural shift toward GenAI-integrated commercialization and a wider client pyramid positions the company to capture a larger share of the life sciences outsourcing market.
⚠ அபாய எச்சரிக்கைகள்
EBITDA margin compression (down 330 bps YoY)
High industry concentration (91.6% revenue from Biopharma)
Potential wage inflation impacting delivery costs
👀 கவனிக்க வேண்டியவை
Monitor the trajectory of EBITDA margins in upcoming quarters to see if they return to the 18-20% historical range as recent investments in sales and GenAI platforms mature. Watch for the execution of the 'Content Super App' and other AI-native products as drivers for future operating leverage.
Indegene reported a robust 39.7% YoY revenue growth in Q1 FY27, reaching ₹1,063.1 crore, up from ₹760.8 crore in the previous year. However, Net Profit remained stagnant at ₹116.2 crore compared to ₹116.4 crore YoY, reflecting margin pressure as employee expenses surged 36.8% to ₹659.1 crore. The company also confirmed the full utilization of its ₹724.6 crore IPO proceeds and the allotment of 12,451 shares under its ESOP scheme.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndegene released its Q1 FY27 financial results showing strong top-line growth but flat profitability, alongside completing its IPO fund utilization.
ஏன் இது முக்கியம்The results highlight a significant scale-up in operations (nearly 40% revenue growth) but also underscore the challenge of rising costs in the life sciences services sector, which is currently capping profit growth.
📅 குறுகிய காலம்The stock may see mixed reactions as the market weighs impressive revenue growth against stagnant net profit and high operating expenses.
📈 நீண்ட காலம்The company's expansion into mid-sized pharma and AI-integrated platforms supports long-term growth, but margin recovery is essential for a structural re-rating.
⚠ அபாய எச்சரிக்கைகள்
High employee cost concentration
Stagnant YoY net profit despite high revenue growth
High client concentration with top 20 biopharma contributing 65.5% of revenue
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to translate high revenue growth into bottom-line profits, specifically looking for stabilization in employee costs and integration benefits from recent acquisitions.
₹2.25 Final Dividend Proposed; Indegene Schedules 28th AGM for August 13
Indegene Limited has scheduled its 28th Annual General Meeting (AGM) for August 13, 2026, to approve the FY26 financial statements and a final dividend of ₹2.25 per equity share. The company reported a TTM revenue of ₹3,510 Cr and a PAT of ₹401 Cr, maintaining a healthy operating margin of 17.6%. Key agenda items include the re-appointment of CEO Manish Gupta and the appointment of Ms. Jill Mary De Simone as an Independent Director. Shareholders as of the August 7, 2026 cut-off date will be eligible to vote on these resolutions.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the schedule for its 28th AGM and officially proposed a final dividend of ₹2.25 per share for shareholder approval.
ஏன் இது முக்கியம்The AGM is the primary forum for shareholders to approve the company's financial performance and leadership changes, while the dividend confirms the company's ability to return cash to shareholders from its ₹401 Cr annual profit.
Final Dividend: ₹2.25 per shareDividend Yield (at ₹510.9): 0.44%TTM வருவாய்: ₹3510 கோடிTTM PAT: ₹401 கோடிCut-off Date: ஆகஸ்ட் 7, 2026
📅 குறுகிய காலம்The stock may see minor positive sentiment leading up to the dividend record date, though the yield is relatively low at current market prices.
📈 நீண்ட காலம்The company's focus on scaling its Enterprise Commercial segment (26.2% YoY growth) and AI integration remains the primary structural driver beyond routine AGM matters.
⚠ அபாய எச்சரிக்கைகள்
High client concentration with 65.5% revenue from top 20 biopharma
Potential margin pressure from US policy changes like the Inflation Reduction Act (IRA)
👀 கவனிக்க வேண்டியவை
Investors should note the cut-off date of August 7, 2026, for dividend eligibility and monitor the AGM proceedings for updates on the integration of recent acquisitions like BioPharm and WARN & Co.
₹2.25 Final Dividend: Indegene Sets July 31 as Record Date
Indegene Limited has fixed July 31, 2026, as the record date for a final dividend of ₹2.25 per equity share for the financial year ended March 31, 2026. This dividend, representing a 112.5% payout on the face value of ₹2, is subject to shareholder approval at the upcoming 28th Annual General Meeting (AGM) scheduled for August 13, 2026. Additionally, the company announced the reconstitution of its Audit, Risk Management, and Investment committees effective July 15, 2026, to align with changes in board composition.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndegene has formalized the timeline for its FY26 final dividend payment and updated its internal board committee structures.
ஏன் இது முக்கியம்The announcement provides certainty regarding the timing of shareholder payouts and demonstrates routine corporate governance through committee updates.
Final Dividend: ₹2.25 per shareடிவிடெண்ட் ஈல்ட்: 0.44%ரெக்கார்ட் தேதி: 31-ஜூலை-2026AGM Date: 13-ஆக.-2026Face Value: ₹2
📅 குறுகிய காலம்The stock is likely to see routine trading activity around the record date as investors position for the dividend payout.
📈 நீண்ட காலம்Limited; this is a routine administrative and dividend announcement that does not alter the company's structural growth trajectory in life sciences outsourcing.
👀 கவனிக்க வேண்டியவை
Investors seeking the dividend must hold the shares before the ex-dividend date (typically one business day prior to the July 31 record date). Monitor the AGM on August 13 for management commentary on the integration of recent acquisitions like BioPharm and WARN & Co.
Indegene Reports FY26 Revenue of ₹35.1 Bn with 29.4% 5-Year CAGR
Indegene Limited has released a comprehensive investor presentation highlighting its FY26 performance, featuring revenue of INR 35.1 billion and a 29.4% CAGR since FY21. The company maintains a strong financial profile with an adjusted EBITDA margin of 19.4% and a zero-debt balance sheet. Strategically, Indegene is positioning itself as a key AI-embedded partner for the top 20 global pharmaceutical companies, aiming to capture a significant share of the $100 billion projected outsourced life sciences market by 2030.
முக்கிய அம்சங்கள்
Revenue reached INR 35,105 million in FY26, growing at a 29.4% CAGR over five years.Maintained high cash efficiency with an OCF to PAT ratio of 162% and an adjusted EBITDA margin of 19.4%.Client base expanded to 91 active relationships, with revenue from Top-20 pharma clients tripling since FY21 to INR 25.2 billion.Revenue per employee stands at $74.7K, supported by a Net Revenue Retention (NRR) consistently above 100%.Targeting a $54B to $100B market opportunity driven by the centralization of pharma sales and marketing functions through AI.
👀 கவனிக்க வேண்டியவை
Investors should note the company's strong cash conversion and zero-debt status, which provides significant headroom for its M&A-led growth strategy. The focus on AI-driven centralization in pharma marketing suggests a sustainable competitive advantage over traditional agencies.
Indegene reported a strong FY26 with annual revenue reaching ₹35,105 million, a 23.6% YoY growth in INR terms. The company achieved a significant milestone in Q4, with quarterly revenue exceeding ₹1,000 crores for the first time in its history. Growth was driven by deepening relationships with top 20 global pharma firms and a 30% increase in customers contributing over $1 million. Management highlighted a major productivity boost, with revenue per employee rising to $75,000, supported by GenAI-led innovation and outcome-based pricing models.
முக்கிய அம்சங்கள்
FY26 revenue grew 23.6% YoY to ₹35,105 million, with Q4 revenue crossing the ₹1,000 crore mark.Active customer base expanded from 73 to 91, with 53 customers now contributing over $1 million in annual revenue.Revenue per employee increased to $75,000 from $56,000 three years ago, driven by AI integration and 'Transform AI' program.Secured a multi-year omnichannel deal exceeding $10 million in ACV and a strategic 'Tectonic' engagement with its largest client.Demonstrated GenAI capability by reducing agency-style creative workflows from 3 months to just 3 days in pilot programs.
👀 கவனிக்க வேண்டியவை
Investors should view the strong revenue growth and productivity gains as a sign of successful AI adoption and market leadership in life sciences services. Monitor the conversion of the $10M+ ACV deal and the potential for the largest client to hit the $50M mark in FY27 as key growth catalysts.
Indegene Receives Income Tax Demand of ₹43.69 Crore for AY 2023-24
Indegene Limited has received a final assessment order from the Income Tax Department for Assessment Year 2023-24, raising a demand of INR 43.69 crore including interest. The demand stems from transfer pricing adjustments totaling INR 123.41 crore made to the company's returned income. Indegene is contesting the order through the Mutual Agreement Procedure (MAP) under the India-USA Double Taxation Avoidance Agreement and domestic appellate channels. The company expects no material adverse impact on its financial position or operations from this development.
முக்கிய அம்சங்கள்
Total income tax demand of INR 43,68,84,410 (approx. ₹43.69 Cr) including interest.Transfer pricing adjustments made to returned income amount to INR 123,41,10,559 (approx. ₹123.41 Cr).Assessment pertains to AY 2023-24, corresponding to the Financial Year 2022-23.Company has filed for resolution via Mutual Agreement Procedure (MAP) under India-USA DTAA.Management maintains that current tax positions are well-supported and expects no material liability.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the MAP and domestic appeals, as transfer pricing disputes are common for global service firms and often take time to resolve. No immediate action is required as the company is actively contesting the demand.
Indegene Named Leader in ISG Provider Lens for Life Sciences Digital Services for 3rd Year
Indegene has been recognized as a Leader in the ISG Provider Lens 2026 report for Life Sciences Digital Services, marking its third consecutive year in this position. The recognition highlights the company's expertise in using AI and GenAI through its proprietary NEXT and Cortex platforms to modernize commercial operations for biopharma firms. Indegene currently serves the world's top 20 biopharma companies, providing integrated, data-driven commercial models. This validation by a global research firm reinforces Indegene's competitive moat in a highly specialized and regulated niche.
முக்கிய அம்சங்கள்
Recognized as a Leader in ISG Provider Lens for the 3rd consecutive yearProprietary platforms NEXT and Cortex highlighted for AI and GenAI integrationIndegene serves the world's top 20 biopharma companies globallyFocus on digital evolution across planning, content, engagement, and analytics
👀 கவனிக்க வேண்டியவை
This recognition validates Indegene's technological leadership; investors should monitor if this helps secure larger contracts or higher margins within the global biopharma sector.
Indegene Limited has announced its audited financial results for the quarter and full year ended March 31, 2026. The Board recommended a final dividend of Rs. 2.25 per equity share (112.5% of face value), subject to shareholder approval. Additionally, the company approved the allotment of 52,951 securities under its ESOP and RSU 2020 schemes. The statutory auditors, Deloitte Haskins & Sells, have issued an unmodified opinion on the consolidated financial statements, indicating no major accounting discrepancies.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs. 2.25 per equity share of Rs. 2 each for FY 2025-26Allotted 52,951 securities pursuant to ESOP Scheme 2020 and RSU Scheme 2020Audited standalone and consolidated financial results for Q4 and FY26 approved with an unmodified opinionApproved amendments to 19 key corporate policies including Insider Trading and Risk ManagementDividend payment to be completed within 30 days post-approval at the ensuing AGM
👀 கவனிக்க வேண்டியவை
Investors should monitor the record date for the Rs. 2.25 dividend and review the detailed P&L statement to assess margin trends. The clean audit report and consistent dividend payout reflect stable corporate governance.
Indegene reported a strong FY26 with revenue growing 23.6% YoY to ₹35,105 million, marking its strongest growth in three years. Adjusted EBITDA stood at ₹6,793 million with a steady margin of 19.4%, while the company achieved a high cash conversion with OCF to PAT at 162%. The company significantly expanded its client base to 91 active relationships, including 53 accounts generating over $1 million in revenue. Management highlighted the successful integration of acquisitions and a robust GenAI-led pipeline heading into FY27.
முக்கிய அம்சங்கள்
Revenue re-accelerated to 23.6% growth in FY26 compared to 9.6% in FY25, crossing the ₹1,000 crore quarterly mark in Q4.Adjusted EBITDA grew 20.8% YoY to ₹6,793 million, maintaining a resilient margin profile between 19-20%.The $1M+ revenue client base expanded by 29% YoY to 53 accounts, the highest addition in four years.Revenue productivity improved by 11.8% to $74.7K per employee, driven by operational leverage and GenAI scaling.Board recommended a final dividend of ₹2.25 per share, representing a 12.5% increase over the previous year.
👀 கவனிக்க வேண்டியவை
Investors should note the strong re-acceleration in revenue and high cash conversion as signs of operational strength. The company's successful expansion of its $1M+ client base and rising revenue per employee suggest a scalable business model with high earnings quality.
Indegene reported a strong Q4 FY26 with quarterly revenue crossing the ₹1,000 crore mark for the first time, reaching ₹1,003.4 crore. For the full year FY26, revenue grew 23.6% to ₹3,510.5 crore, supported by 53 clients contributing over $1 million in annual revenue. While annual Adjusted EBITDA margins saw a slight compression to 19.4%, cash flow from operations surged by 47.3% YoY to ₹6,508 million. The board has recommended an increased final dividend of ₹2.25 per share.
முக்கிய அம்சங்கள்
Quarterly revenue grew 32.8% YoY to ₹1,003.4 crore, surpassing the ₹1,000 crore milestone.Full-year FY26 revenue reached ₹3,510.5 crore, representing a 23.6% YoY growth in INR terms.Cash flow from operations increased by 47.3% YoY to ₹6,508 million with a 162% cash conversion ratio.Board recommended a final dividend of ₹2.25 per equity share, a 12.5% increase over the previous year.Strong deal momentum in Q4 with 1 deal over $3M ACV and 7 deals in the $1-3M range.
👀 கவனிக்க வேண்டியவை
Investors should take note of the robust revenue growth and exceptional cash flow generation which underscores the company's operational efficiency. The stock remains a strong play in the life sciences digital transformation space, though monitoring margin stability in upcoming quarters is advised.
Indegene to Acquire Two UK Entities for GBP 2.7 Million in Internal Restructuring
Indegene Limited is streamlining its corporate structure by acquiring 100% equity in two UK-based subsidiaries, DT Associates Research and Consulting Services and Trilogy Writing and Consulting, for a combined cash consideration of approximately GBP 2.7 million. This internal restructuring will bring both entities under Indegene Healthcare UK Limited. DT UK reported FY25 revenue of GBP 6.4 million, while Trilogy UK reported GBP 2.34 million. The transaction is expected to be completed by March 31, 2026, and is classified as a related party transaction conducted at arm's length.
முக்கிய அம்சங்கள்
Acquisition of 100% stake in DT UK for GBP 2,001,000 and Trilogy UK for GBP 702,348DT UK revenue declined to GBP 6.4 million in FY25 from GBP 9.2 million in FY24Trilogy UK showed revenue growth, reaching GBP 2.34 million for the period ending March 2025The move is primarily for internal restructuring to consolidate UK-based life science service operationsTotal cash consideration for both acquisitions is approximately GBP 2.703 million
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine corporate cleanup to simplify the subsidiary hierarchy. No immediate impact on consolidated financials is expected as the entities were already part of the group.
Indegene Q3 FY26 Revenue Grows 30.8% YoY to INR 9,421 Mn; Large Deal Wins Boost Outlook
Indegene reported a robust Q3 FY26 with total revenue of INR 9,421 million, a 30.8% YoY increase, including 18.3% organic growth. The company successfully integrated BioPharm and reported an adjusted EBITDA margin of 18.5%, with plans to reach 20% in 6-8 quarters. Significant deal wins were highlighted, including a $20 million TCV contract and a $10 million annual revenue engagement. Customer metrics improved with $1M+ accounts rising to 52 and revenue per employee exceeding $70,000.
முக்கிய அம்சங்கள்
Revenue increased 30.8% YoY to INR 9,421 million; organic growth was 18.3% YoY.Adjusted EBITDA margin stood at 18.5%, up 30 bps QoQ despite acquisition-related costs.Secured 7 large deals exceeding $1M ACV each, including a major $20M TCV biotech partnership.$1M+ customer count grew by 12 to 52; active customers increased to 86.Revenue per employee surpassed $70,000, driven by specialized AI-led platforms and domain expertise.
👀 கவனிக்க வேண்டியவை
Maintain a positive outlook given the strong deal pipeline and organic growth momentum. Watch for EBITDA margin expansion towards the 20% target as acquisition synergies and large deals scale.
Indegene Q3 Revenue Jumps 31% YoY to ₹9,421 Million; Completes ₹9,146 Million BioPharm Acquisition
Indegene Limited reported a strong 30.8% YoY growth in revenue from operations, reaching ₹9,421 million for Q3 FY26. Net profit for the quarter stood at ₹1,029 million, showing stability despite the integration of the BioPharm acquisition which cost ₹9,146 million ($104 million). The company also announced the allotment of 13,332 equity shares under its RSU 2020 plan and reconstituted key board committees. The nine-month revenue for FY26 has reached ₹25,071 million, compared to ₹20,837 million in the previous year.
முக்கிய அம்சங்கள்
Revenue from operations grew 30.8% YoY to ₹9,421 million in Q3 FY26.Completed acquisition of BioPharm Parent Holding Inc. for ₹9,146 million ($104 million) on October 1, 2025.Consolidated net profit for the quarter recorded at ₹1,029 million with an EPS of ₹4.29.Allotted 13,332 equity shares pursuant to the RSU 2020 Plan.Nine-month total income reached ₹25,683 million, up from ₹21,653 million YoY.
👀 கவனிக்க வேண்டியவை
Investors should view the significant revenue growth and successful M&A integration as positive indicators of scale. Monitor the EBITDA margins in upcoming quarters to ensure the BioPharm acquisition is yielding the expected operational efficiencies.
Indegene Q3 FY26 Revenue Surges 30.8% YoY to ₹9,421 Mn; First $100M+ Revenue Quarter
Indegene reported a strong Q3 FY26 with revenue growing 30.8% YoY to ₹9,421 million, marking its first quarter exceeding $100 million in revenue. While adjusted EBITDA grew 15.7% YoY to ₹1,747 million, reported PAT remained relatively flat at ₹1,026 million due to one-time acquisition costs and higher non-cash amortization. The company successfully completed the acquisitions of BioPharm (US) and Warn & Co. (UK), which contributed to the growth in the Enterprise Commercial Solutions segment. Management highlighted record productivity with revenue per employee crossing the $70,000 annual mark, driven by AI integration.
முக்கிய அம்சங்கள்
Revenue from operations grew 30.8% YoY to ₹9,421 million ($106.1 million).Adjusted EBITDA rose 15.7% YoY to ₹1,747 million, though margins compressed slightly to 18.5%.Active client base expanded to 86, with 52 clients now contributing over $1 million in annual revenue.Cash and investments remain strong at ₹13,954 million even after acquisition-related outflows.Revenue per employee reached an industry-leading $70,000+ annually due to AI-led productivity gains.
👀 கவனிக்க வேண்டியவை
Investors should look past the transient PAT flatness caused by acquisition accounting and focus on the robust 30%+ top-line growth and increasing client mining. The company's ability to scale revenue per employee through AI suggests significant long-term operating leverage.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
